공고 • Jul 28
Rocket Doctor AI Inc. announced that it expects to receive CAD 2 million in funding Rocket Doctor AI Inc. to announce a non-brokered private placement of unsecured convertible debentures in the amount of CAD 1,000 each in the aggregate principal amount of up to CAD 2,000,000 on July 28, 2026. The Debentures will bear interest from the date of issuance at a rate of 12.0% per annum, calculated and payable on maturity which is 12 months following the issuance of the Debentures. The principal amount of the Debentures, together with any accrued and unpaid interest, may be converted, in whole or in part at the election of the holder, into units of the Company at a conversion price of CAD 0.70 per Unit on the earlier of: (i) the business day immediately preceding the Maturity Date; and (ii) the business day immediately preceding the date fixed for redemption of the Debentures by the Company, if any, subject to the terms therein. Each Unit will consist of one common share in the capital of the Company and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at an exercise price of CAD 0.75 per Warrant Share for a period of 12 months from the date of issuance pursuant to the terms therein. The Warrant Expiry Date may be accelerated in the event the Shares trade on the CSE at CAD 0.75 or more per Common Share for any 10 consecutive trading days, and, upon delivery of a notice to the holder, the Warrant Expiry Date will be accelerated to 5:00pm on the date that is 10 calendar days from the date of delivery of an acceleration notice to the holder. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the CSE. The securities issued in connection with the Offering will be subject to applicable statutory hold periods imposed under applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions and may close in one or more tranches. The Company anticipates paying finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Any finders' fees payable will be in accordance with the policies of the CSE. 공고 • Jul 07
Rocket Doctor Ai Inc. Announces CFO Changes Rocket Doctor AI Inc. had appointed Mr. Andrew Lau, CPA, CA as Chief Financial Officer, effective July 6, 2026. Mr. Lau brought over 18 years of capital markets, corporate finance, and public company experience to Rocket Doctor AI. Throughout his career, he had held executive finance leadership roles with high-growth technology and life sciences companies, where he had led corporate finance, treasury, financial reporting, corporate development, and public company initiatives. Mr. Lau began his career with Deloitte LLP, where he earned his Chartered Professional Accountant designation, before joining RBC Capital Markets as an investment banker specializing in M&A and equity financing transactions. Over the course of his career, he had advised on and executed more than $700 million in M&A and capital markets transactions and had played a key role in helping emerging growth companies scale, strengthen their financial operations, and access the public markets. Mr. Lau replaced Mr. Chris Cherry, who stepped down as Interim CFO to return to his role as Chair of the Audit Committee while continuing his service as a director. 공고 • Jun 17
Treatment.Com Inc Receives Year 2 Funding from National Institute on Minority Health and Health Disparities Rocket Doctor AI Inc. announced that Treatment.com Inc., in collaboration with Rush River Research, had received confirmation of second-year funding from the National Institute on Minority Health and Health Disparities, part of the National Institutes of Health. The funding granted follows the successful completion of the program’s first-year milestones and extends support for the development of an AI-powered family medical history tool designed to make preventive care more accurate, accessible, and culturally responsive. The second-year award provides Treatment with in excess of USD 250,000 in additional support, with the program agreement now extended through May 31, 2027. This extension provides Treatment with over USD 500,000 to enhance its Global Library of Medicine and AI-powered clinical tools. The two-year project is supported by a highly competitive Small Business Innovation Research grant with a total award value of approximately USD 2 million. As part of the Year 2 extension, Treatment will receive more than USD 250,000 in additional funding, bringing its total program support to more than USD 500,000. The project agreement now extends through May 31, 2027. 공고 • Jan 23
Rocket Doctor AI Inc. announced that it has received CAD 5.2 million in funding On January 22, 2026,Rocket Doctor AI Inc. closed the transaction. In connection with the closing of the transaction, the company paid to certain finders cash commission of CAD 198,800 and issued 284,000 non-transferrable warrants of the Company exercisable at any time until January 22, 2027 to acquire one Common Share at an exercise price of CAD 0.85, subject to adjustment in certain events. The securities issued in the Offering are not subject to a hold period in accordance with applicable Canadian securities laws. 공고 • Dec 09
Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta Rocket Doctor AI Inc. announced a new partnership with the CAN Health Network to test its AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities. The project will launch at up to four primary care sites in Alberta to help physicians deliver faster, evidence-based, and more efficient care. The program was developed in accordance with Health Cities' need for an integrated, AI-powered solution capable of analyzing diverse data sources, automating routine tasks, and delivering real-time clinical recommendations. The project, running from November 2025 to March 2026, involves approximately 20 clinicians and aims to set the foundation for a potential full provincial rollout in 2026. As a CAN Health Network Primary Care Edge, Health Cities creates an environment where innovative solutions can be co-developed, validated, and adopted to address real-world health challenges. The initiative rolls out in three phases, beginning with AI-powered patient intake through a website-embedded chatbot, followed by real-time clinician support during visits, and ultimately integration with electronic medical records (EMRs). Rocket Doctor AI's Global Library of Medicine (GLM) is a clinically-validated decision engine developed with input from hundreds of physicians to assist providers with triage, differential diagnosis, and evidence-based care planning. This project comes at a critical time for Alberta's healthcare system, where staffing shortages, limited access to primary care, and increasing patient loads continue to strain clinics across the province. Recent data shows that one in five Albertans lacks a family physician, with many communities facing long wait times for basic care. This project aims to directly address these challenges by supporting clinicians with intelligent, AI-driven tools that improve efficiency and patient access. Key anticipated outcomes include a 25-40% reduction in physician intake time, as well as improved patient satisfaction through faster and clearer communication. The CDSS is also expected to significantly reduce physicians' administrative workload, including less time on charting, documentation, and billing. Rocket Doctor AI's platform will be hosted in secure, Canadian-based data centres, aligned with HIPAA, PIPEDA, and Alberta's Health Information Act (HIA). The modular system architecture ensures future growth, with the capability to scale across Alberta's 4,400 providers and beyond. This project is made possible through funding and support from the CAN Health Network, a federally funded initiative designed to help Canadian companies scale innovative healthcare solutions domestically. The partnership underscores Rocket Doctor AI's commitment to advancing equitable access to care, supporting overburdened clinicians, and modernizing healthcare delivery through responsible AI innovation. A Commercialization Project Agreement was entered into by the parties on 12th November 2025. The Agreement details the intent of the parties to collaborate in jointly delivering a Commercialization Project. Either party may propose amendments or terminate this Agreement upon written notice. 공고 • Dec 06
Rocket Doctor AI Inc. Announces Change of Chief Financial Officer, Effective December 8, 2025 Rocket Doctor AI Inc. announced that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025. Mr. Cherry is currently the Company’s Chair of the Audit Committee. 
